"If you bring powerful technology to a problem that is well understood, then you can really make a difference." - Marc Lajoie, CEO at Outpace Bio
Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Marc Lajoie, as they discuss how de novo proteins can be used to reprogram immune cells.
Tune in today!

"If you bring powerful technology to a problem that is well understood, then you can really make a difference." - Marc Lajoie, CEO at Outpace Bio Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Marc Lajoie, as they discuss how de novo proteins can be used to reprogram immune cells. Tune in today!

"If&nbsp;you bring powerful technology to a problem that is well understood, then you can really make a difference." - Marc Lajoie, CEO at Outpace Bio
Welcome to the latest episode of Biorasi's Few &amp; Far Between podcast. Join host Chris O'Brien and guest, Marc Lajoie, as they discuss how&nbsp;de novo proteins can be used to reprogram immune cells.
Tune in today!

Episode 47 - Marc Lajoie, CEO at Outpace Bio

Welcome to Few & Far Between! Chris O'Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.

Science

Medicine

Health & Fitness

Mental Health

Life Sciences

Welcome to Few &amp; Far Between! Chris O'Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.

Share Episode 47 - Marc Lajoie, CEO at Outpace Bio

Sign up to save your podcasts

Episode 47 - Marc Lajoie, CEO at Outpace Bio

Episode 47 - Marc Lajoie, CEO at Outpace Bio